Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Abbott Laboratories Senior Vice President Eric Shroff reported equity awards that increase his direct holdings. He received an option for 44,821 shares at an exercise price of $0.00 and a grant of 10,873 common shares, both characterized as awards or other acquisitions.
The 10,873-share grant is a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program with a three-year term and no more than one-third vesting in any year, tied to a minimum return on equity target. The 44,821-share employee stock option, also under the 2017 program, becomes exercisable in annual increments of 14,940 shares on February 24, 2027 and February 24, 2028, and 14,941 shares on February 24, 2029.
ABBOTT LABORATORIES executive Christopher J. Scoggins reported equity awards consisting of stock options and performance-based shares. He received an employee stock option for 76,273 common shares at an exercise price of $0.0000 per share, granted under the Abbott Laboratories 2017 Incentive Stock Program.
The option becomes exercisable in three annual increments of 25,424 shares on February 24, 2027, 25,424 shares on February 24, 2028, and 25,425 shares on February 24, 2029. He was also granted 18,502 common shares as a performance-based restricted stock award with a three-year term, with no more than one‑third vesting in any year upon Abbott reaching a minimum return on equity target, and the award allows shares to be withheld for taxes.
ABBOTT LABORATORIES executive Daniel Gesua Sive Salvadori reported awards of equity-based compensation. He received an option to buy 89,226 Abbott shares at an exercise price of $0.00 per share under the 2017 Incentive Stock Program, with the option becoming exercisable in three equal annual installments of 29,742 shares on February 24, 2027, February 24, 2028, and February 24, 2029. He also acquired 21,644 common shares as a performance-based restricted stock award with a three-year term, where no more than one-third of the award can vest in any one year, subject to Abbott reaching a minimum return on equity target, and the award allows shares to be withheld to cover taxes.
ABBOTT LABORATORIES executive Louis H. Morrone reported equity awards granted on February 24, 2026. He acquired an option to buy 63,561 Abbott shares at an exercise price of $0.00 per share and a grant of 15,418 common shares, both reported as direct ownership.
The 15,418-share award is performance-based restricted stock under the Abbott Laboratories 2017 Incentive Stock Program with a 3‑year term, where no more than one‑third can vest in any year and vesting depends on Abbott reaching a minimum return on equity target, and it allows shares to be withheld for taxes. The stock option, also under the 2017 Incentive Stock Program, was granted in a transaction exempt from Section 16 under Rule 16b‑3 and becomes exercisable in three equal annual installments of 21,187 shares on February 24, 2027, February 24, 2028, and February 24, 2029. The filing also notes an indirect holding of 12 Abbott shares in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.
Moreland Mary K reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive vice president Mary K. Moreland reported equity awards on common stock. She received an employee stock option covering 57,512 shares that vests in three annual installments starting February 24, 2027, and a performance-based restricted stock award of 13,951 shares with a three-year term tied to return-on-equity targets.
Abbott Laboratories executive John A. McCoy Jr., Vice President and Controller, reported equity awards on February 24, 2026. He acquired an employee stock option for 22,151 options with no purchase price, which vests in three annual installments beginning in 2027. He also received a performance-based restricted stock award of 5,373 common shares that can vest over three years if Abbott meets a minimum return-on-equity target, with shares eligible to be withheld for taxes. Separately, he reported 58 common shares held indirectly in the Abbott Laboratories Stock Retirement Trust as of that date.
Abbott Laboratories Chairman and CEO Robert B. Ford reported equity awards rather than open-market trades. He acquired 344,066 options with a zero-dollar grant price under the Abbott Laboratories 2017 Incentive Stock Program, scheduled to become exercisable in three equal annual installments starting on February 24, 2027.
Ford also received a performance-based restricted stock award of 83,464 common shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target. An additional 216,203 common shares are reported as held indirectly through the Ford Family Trust, where he serves as co-trustee.
Earnhardt Lisa D reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive Lisa D. Earnhardt, EVP and Group President, reported equity awards on February 24, 2026. She was granted stock options covering 111,533 options and a performance-based restricted stock award of 27,056 common shares under the Abbott Laboratories 2017 Incentive Stock Program.
The restricted stock award has a three-year term, with no more than one-third vesting in any year and vesting tied to Abbott reaching a minimum return-on-equity target. The award allows shares to be withheld for taxes. The stock option becomes exercisable in increments of 37,177 and 37,178 shares on February 24, 2027, February 24, 2028, and February 24, 2029.
Cushman Elizabeth C. reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive Elizabeth C. Cushman, EVP, GC and Secretary, reported equity awards on February 24, 2026. She received an employee stock option for 61,964 options under the Abbott 2017 Incentive Stock Program, exercisable in three annual installments starting in 2027. She was also granted 15,031 performance-based restricted shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target and allowing shares to be withheld for taxes.